Rosetta Genomics offers MicroRNA-based mesothelioma diagnostic test

Press Release from Rosette Genomics

Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-BasedDiagnostic Test: miRview(TM) meso

The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer

REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.

To order the test, physicians may contact 1-888-522-7971, or visit the company's website http://www.rosettagenomics.com.

"I am very excited to finally see a molecularly-based test that can objectively differentiate mesothelioma from several types of carcinomas in the lung with such high level of accuracy" noted Harvey Pass, MD, Division Chief for Thoracic Surgery and Thoracic Oncology at the New York University Langone Medical Center. "Ruling out Mesothelioma from lung cancer for individuals that were exposed to asbestos can be difficult and challenging. I am sure that this test will become an important tool for both oncologists and pathologists in obtaining the right diagnosis in these patients."

Malignant pleural mesothelioma is directly linked to exposure to asbestos particles, as well as to various heavy metals. Rescue workers, shipyard workers, and miners are at increased risk of developing mesothelioma. Currently, there is no single diagnostic test that is entirely conclusive for this differentiation. In addition, pathological diagnosis may suffer from significant inter-observer variability, and in the absence of a single specific and reliable test, mesothelioma can be difficult to identify from other cancers.

miRview(TM) meso differentiates mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung. Currently, there is no single diagnostic test that is entirely conclusive for this differentiation. Each year, approximately 130,000 patients in the United States are diagnosed with adenocarcinoma of the lung. miRview(TM) meso is available for $3170.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

To receive a FREE Mesothelioma Web information packet** or to make a request, please fill out the following form :

**For a FREE information packet including treatments, clinical trials, and specialists, please complete the form above or call a Mesothelioma Web coordinator at 1-877-367-6376.

News

Resources

This site complies with the HONcode standard for trustworthy health information: verify here

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376